aTYR PHARMA INC SEC filings ATYR
aTYR PHARMA INC has 755 filings in SEC EDGAR's recent list, going back to Sep 23, 2005. Its latest annual report, Form ARS, was filed on Mar 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 6, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 6, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 18, 2025 | — |
| CORRESP | Letter to the SEC | Aug 13, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2024 | — |
| CORRESP | Letter to the SEC | Jun 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 6, 2024 | — |
| EFFECT | Filing | Nov 20, 2023 | — |
| CORRESP | Letter to the SEC | Nov 16, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2023 | — |
| EFFECT | Filing | Apr 8, 2022 | — |
| CORRESP | Letter to the SEC | Apr 5, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2022 | — |
| EFFECT | Filing | Aug 23, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 23, 2021 | — |
| CORRESP | Letter to the SEC | Aug 19, 2021 | — |
| EFFECT | Filing | Nov 23, 2020 | — |
| CORRESP | Letter to the SEC | Nov 19, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2020 | — |
| EFFECT | Filing | Sep 28, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2020 | — |
| CORRESP | Letter to the SEC | Sep 24, 2020 | — |
| POS EX | Filing | Feb 6, 2020 | — |
| EFFECT | Filing | Feb 5, 2020 | — |
| CORRESP | Letter to the SEC | Feb 3, 2020 | — |
| CORRESP | Letter to the SEC | Feb 3, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2020 | — |
| EFFECT | Filing | Jun 20, 2019 | — |
| CORRESP | Letter to the SEC | Jun 19, 2019 | — |
| UPLOAD | Letter from the SEC | May 28, 2019 | — |
| CT ORDER | Filing | Apr 17, 2018 | — |
| EFFECT | Filing | Sep 27, 2017 | — |
| CORRESP | Letter to the SEC | Sep 25, 2017 | — |
| CT ORDER | Filing | Sep 21, 2017 | — |
| D | Filing | Sep 15, 2017 | — |
| CT ORDER | Filing | Apr 14, 2017 | — |
| EFFECT | Filing | Jun 22, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2016 | — |
| CORRESP | Letter to the SEC | Jun 20, 2016 | — |
| CT ORDER | Filing | Nov 30, 2015 | — |
| CT ORDER | Filing | May 8, 2015 | — |
| EFFECT | Filing | May 6, 2015 | — |
| CERTNAS | Auto-generated paper document | May 6, 2015 | — |
| 8-A12B | Filing | May 6, 2015 | — |
| CORRESP | Letter to the SEC | May 5, 2015 | — |
| CORRESP | Letter to the SEC | May 4, 2015 | — |
| CORRESP | Letter to the SEC | May 4, 2015 | — |
| UPLOAD | Letter from the SEC | May 4, 2015 | — |
| CORRESP | Letter to the SEC | Apr 17, 2015 | — |
| CORRESP | Letter to the SEC | Apr 6, 2015 | — |
| D | Filing | Apr 2, 2015 | — |
| UPLOAD | Letter from the SEC | Feb 18, 2015 | — |
| DRSLTR | Filing | Feb 2, 2015 | — |
| DRS/A | Filing | Feb 2, 2015 | — |
| UPLOAD | Letter from the SEC | Jan 21, 2015 | — |
| DRSLTR | Filing | Dec 22, 2014 | — |
| DRS | Filing | Dec 22, 2014 | — |
| REGDEX | Auto-generated paper document | Dec 13, 2006 | — |
| REGDEX | Auto-generated paper document | Sep 23, 2005 | — |
Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ATYR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1339970
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.